Skip to content

rTMS to Enhance Cognitive Performance and Promote Resilience

Safety and Efficacy of an Accelerated Protocol of Intermittent Theta Burst Transcranial Magnetic Stimulation (TMS) to Enhance Performance and Promote Resilience in Astronauts: Study 1

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04123496
Enrollment
38
Registered
2019-10-11
Start date
2019-11-21
Completion date
2021-10-27
Last updated
2025-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognition, Stress Reaction

Keywords

cognition, adult, prefrontal cortex, Transcranial Magnetic Stimulation, Stress, Psychological, memory, attention

Brief summary

The purpose of this study is to determine the most effective dose of brief, non-invasive brain stimulation (repetitive transcranial magnetic stimulation, rTMS) for improving cognitive functions such as attention and memory as well as to improve the ability to recover from stressful situations (stress resilience).

Detailed description

Repetitive transcranial magnetic stimulation (rTMS) works by rapidly turning a focused magnetic field on-and-off repeatedly over your head, which passes directly through your hair, scalp, and skull and onto your brain, and can temporarily increase brain activity under the magnetic field. Repetitive transcranial magnetic stimulation (rTMS) is an FDA approved treatment for depression, and is used commonly to treat people for their depression. The rTMS treatment regime used in this study is different from the FDA approved treatment because you will receive up to ten treatments per day over five days instead of the FDA approved rTMS treatment regime of 25 treatments over 25 days. This sort of accelerated or high dose protocol has been shown to be safe and effective in the treatment of depression. We are hoping to find out if this treatment can be used as a treatment for improving cognitive function and stress resilience.

Interventions

DEVICErTMS

Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.

Sponsors

National Aeronautics and Space Administration (NASA)
CollaboratorFED
The Translational Research Institute for Space Health (TRISH)
CollaboratorUNKNOWN
Medical University of South Carolina
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
22 Years to 55 Years
Healthy volunteers
Yes

Inclusion criteria

1. No history of mental or physical illness 2. No implanted metal in the body 3. College graduates (Associates degree or higher) 4. Negative urine pregnancy test, if female subject of childbearing potential 5. Able to read and understand questionnaires and informed consent

Exclusion criteria

1. Any current psychiatric diagnosis or current Clinical Global Impression ratings of psychiatric illness \> 1 2. Current physical illness 3. History of CNS disease, concussion, overnight hospitalization, tumors, seizures, meningitis, encephalitis, abnormal CT/MRI of the brain 4. Moderate to severe traumatic brain injury (TBI) 5. History of a continuing significant laboratory finding 6. Frequent or severe headaches 7. Any history of psychotropic medication prior to study enrollment 8. Females of childbearing potential who are pregnant (by urine HCG), nursing, or who are not using a reliable form of birth control. 9. active participation or plan for enrollment in another evidence-based clinical trial affecting psychosocial function 10. repeated abuse or dependence upon drugs (excluding nicotine and caffeine) 11. implanted devices/ferrous metal of any kind

Design outcomes

Primary

MeasureTime frameDescription
Mean Score of Neurocognitive Performance (Fluid Cognition)Baseline (Day 1)Participants would complete a computerized batteries (Penn Computerized Neuropsychological Battery and NIH Cognition Battery). Tasks would assess the following domains: information-processing speed, executive function, sustained attention/vigilance, verbal memory, working-memory capacity, inhibition/impulsivity, and sensorimotor function. This composite includes all the tests noted above that are fluid ability measures: Flanker, Dimensional Change Card Sort, Picture Sequence Memory, List Sorting and Pattern Comparison. This composite score is derived by averaging the standard scores of each of the measures, and then deriving standard scores based on this new distribution. Higher values (positive changes from baseline) indicate better performance. The T-score has a mean of 50 in the general population and a SD of 10. Scores higher than the mean indicate better performance.
Change From Baseline in Neurocognitive Performance at 1 Week Post Treatment (Fluid Cognition)Post-treatment (within 1 week of completing rTMS)Participants would complete a computerized batteries (Penn Computerized Neuropsychological Battery and NIH Cognition Battery). Tasks would assess the following domains: information-processing speed, executive function, sustained attention/vigilance, verbal memory, working-memory capacity, inhibition/impulsivity, and sensorimotor function. This composite includes all the tests noted above that are fluid ability measures: Flanker, Dimensional Change Card Sort, Picture Sequence Memory, List Sorting and Pattern Comparison. This composite score is derived by averaging the standard scores of each of the measures, and then deriving standard scores based on this new distribution. The T-score has a mean of 50 in the general population and a SD of 10. Scores higher than the mean indicate better performance.
Change From Baseline in Neurocognitive Performance at 1 Month Post Treatment (Fluid Cognition)Post-treatment (within 1 month of completing rTMS)Participants would complete a computerized batteries (Penn Computerized Neuropsychological Battery and NIH Cognition Battery). Tasks would assess the following domains: information-processing speed, executive function, sustained attention/vigilance, verbal memory, working-memory capacity, inhibition/impulsivity, and sensorimotor function. This composite includes all the tests noted above that are fluid ability measures: Flanker, Dimensional Change Card Sort, Picture Sequence Memory, List Sorting and Pattern Comparison. This composite score is derived by averaging the standard scores of each of the measures, and then deriving standard scores based on this new distribution. The T-score has a mean of 50 in the general population and a SD of 10. Scores higher than the mean indicate better performance.

Secondary

MeasureTime frameDescription
Mean Score of Neurocognitive Performance (WINSCAT Composite)Baseline (Day 1)The WINSCAT battery includes 5 subtests: Code Substitution (CDS), Code Substitution Delayed Recognition (CDD), Delayed Matching to Sample (MSP), Mathematical Processing (MTH), and Running Memory Continuous Performance (CPT). Each subtest produces a standardized score (range: 0-100). Composite score is the sum of all subtests (range: 0-500). Higher scores indicate better cognitive performance. Baseline scores reflect initial neurocognitive status. WINSCAT assesses attention, memory, visual processing, and executive function.
Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience ScaleBaseline (Day 1)Participants would complete a series of questionnaires Connor Davidson Resilience Scale is a self-reported scale consisting of 10-items measuring resilience. Respondents rate items on a 5-point Likert scale, ranging from 0 (not true at all) to 4 (true nearly all the time). Each item has a minimum score of 0 and a maximum score of 4. The minimum value is a 0 and the maximum value is a 100. A higher score indicates higher resilience, which indicates a better outcome. -Questions are rated on a scale from 0-4, where a higher score reflects greater resilience.
Mean Score of Neurocognitive Performance (Stress Total Score)Baseline (Day 1)is a 99-item self-report questionnaire assessing emotional and psychological symptoms across 18 subscales. For this outcome, a subset of items was used to assess stress resilience, likely drawn from the Well-Being or related subscales. Each item is rated on a 5-point Likert scale from 1 (Not at all) to 5 (Extremely). Scores were summed across selected items. Minimum possible score: 0 Maximum possible score: 15 Lower scores indicate greater resilience and better emotional functioning. Higher scores indicate greater symptom severity and worse outcomes.
Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10Baseline (Day 1)The investigators will use the Perceived Stress Scale 10 (PSS-10) to assess perceived stress using a 5-point Likert scale. Scoring Instructions: Total score is determined by adding together the scores of each of the four items. Questions 2 and 3 are reverse coded. Questions 1 and 4: 0 = Never; 1 = Almost never; 2 = Sometimes; 3 = Fairly often; 4 = Very often Questions 2 and 3: 4 = Never; 3 = Almost never; 2 = Sometimes; 1 = Fairly often; 0 = Very often. Scores range from 0 to 40 with higher scores indicating more stress.
Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-IIBaseline (Day 1)The Inventory of Depression and Anxiety Symptoms-II (IDAS-II) is a 99-item self-report questionnaire assessing emotional and psychological symptoms across 18 subscales. Each item is rated on a 5-point Likert scale from 1 (Not at all) to 5 (Extremely). In this study, a composite score was calculated by summing responses across multiple relevant subscales (e.g., Dysphoria, Panic, Insomnia, Well-Being) to assess overall emotional distress and stress resilience. Minimum possible score: 99 (if all items scored 1) Maximum possible score: 495 (if all items scored 5) Higher scores indicate greater symptom severity and worse outcomes. Lower scores reflect better emotional functioning and greater resilience.

Countries

United States

Participant flow

Participants by arm

ArmCount
Dose 1
All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 1 is 5 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds. rTMS: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
4
Dose 2
All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 2 is 10 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds. rTMS: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
4
Dose 3
All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 3 is 15 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds. rTMS: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
4
Dose 4
All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 4 is 20 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds. rTMS: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
4
Dose 5
All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 5 is 25 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds. rTMS: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
4
Dose 6
All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 6 is 30 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds. rTMS: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
4
Dose 7
All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 7 is 35 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds. rTMS: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
4
Dose 8
All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 8 is 40 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds. rTMS: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
3
Dose 9
All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 9 is 45 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds. rTMS: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
3
Dose 10
All participants will be randomized to one of 10 doses of accelerated rTMS. All doses are active and within established therapeutic levels of rTMS. Dose 10 is 50 sessions of 600 pulses at 120% of resting motor threshold. Intermittent theta burst triplets at 50 Hz for 2 seconds and repeated every 10 seconds for a total of 190 seconds. rTMS: Device: Repetitive Transcranial Magnetic Stimulation (rTMS) MagVenture MagPro TMS System would be utilized to deliver 3-minute sessions of intermittent theta burst to left dorsolateral prefrontal cortex.
4
Total38

Baseline characteristics

CharacteristicTotalDose 2Dose 1Dose 3Dose 4Dose 5Dose 6Dose 7Dose 8Dose 9Dose 10
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
38 Participants4 Participants4 Participants4 Participants4 Participants4 Participants4 Participants4 Participants3 Participants3 Participants4 Participants
Race/Ethnicity, Customized
African American
5 Participants1 Participants1 Participants0 Participants1 Participants0 Participants1 Participants0 Participants0 Participants1 Participants0 Participants
Race/Ethnicity, Customized
Caucasian
31 Participants3 Participants3 Participants4 Participants3 Participants4 Participants2 Participants3 Participants3 Participants2 Participants4 Participants
Race/Ethnicity, Customized
Other-Egyptian
1 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants1 Participants0 Participants0 Participants0 Participants
Race/Ethnicity, Customized
Other-Vietnamese American
1 Participants0 Participants0 Participants0 Participants0 Participants0 Participants1 Participants0 Participants0 Participants0 Participants0 Participants
Sex: Female, Male
Female
21 Participants3 Participants2 Participants2 Participants3 Participants2 Participants3 Participants2 Participants0 Participants2 Participants2 Participants
Sex: Female, Male
Male
17 Participants1 Participants2 Participants2 Participants1 Participants2 Participants1 Participants2 Participants3 Participants1 Participants2 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
EG005
affected / at risk
EG006
affected / at risk
EG007
affected / at risk
EG008
affected / at risk
EG009
affected / at risk
deaths
Total, all-cause mortality
0 / 40 / 40 / 40 / 40 / 40 / 40 / 40 / 30 / 30 / 4
other
Total, other adverse events
0 / 40 / 40 / 40 / 40 / 40 / 40 / 40 / 30 / 30 / 4
serious
Total, serious adverse events
0 / 40 / 40 / 40 / 40 / 40 / 40 / 40 / 30 / 30 / 4

Outcome results

Primary

Change From Baseline in Neurocognitive Performance at 1 Month Post Treatment (Fluid Cognition)

Participants would complete a computerized batteries (Penn Computerized Neuropsychological Battery and NIH Cognition Battery). Tasks would assess the following domains: information-processing speed, executive function, sustained attention/vigilance, verbal memory, working-memory capacity, inhibition/impulsivity, and sensorimotor function. This composite includes all the tests noted above that are fluid ability measures: Flanker, Dimensional Change Card Sort, Picture Sequence Memory, List Sorting and Pattern Comparison. This composite score is derived by averaging the standard scores of each of the measures, and then deriving standard scores based on this new distribution. The T-score has a mean of 50 in the general population and a SD of 10. Scores higher than the mean indicate better performance.

Time frame: Post-treatment (within 1 month of completing rTMS)

ArmMeasureValue (MEAN)Dispersion
Dose 1Change From Baseline in Neurocognitive Performance at 1 Month Post Treatment (Fluid Cognition)73.333 score on a scaleStandard Deviation 9.292
Dose 2Change From Baseline in Neurocognitive Performance at 1 Month Post Treatment (Fluid Cognition)65.000 score on a scaleStandard Deviation 6.557
Dose 3Change From Baseline in Neurocognitive Performance at 1 Month Post Treatment (Fluid Cognition)68.000 score on a scaleStandard Deviation 11.106
Dose 4Change From Baseline in Neurocognitive Performance at 1 Month Post Treatment (Fluid Cognition)71.250 score on a scaleStandard Deviation 6.5
Dose 5Change From Baseline in Neurocognitive Performance at 1 Month Post Treatment (Fluid Cognition)71.750 score on a scaleStandard Deviation 7.762
Dose 6Change From Baseline in Neurocognitive Performance at 1 Month Post Treatment (Fluid Cognition)68.333 score on a scaleStandard Deviation 4.726
Dose 7Change From Baseline in Neurocognitive Performance at 1 Month Post Treatment (Fluid Cognition)72.333 score on a scaleStandard Deviation 10.263
Dose 8Change From Baseline in Neurocognitive Performance at 1 Month Post Treatment (Fluid Cognition)74.000 score on a scaleStandard Deviation 2.646
Dose 9Change From Baseline in Neurocognitive Performance at 1 Month Post Treatment (Fluid Cognition)73.667 score on a scaleStandard Deviation 3.215
Dose 10Change From Baseline in Neurocognitive Performance at 1 Month Post Treatment (Fluid Cognition)67.500 score on a scaleStandard Deviation 6.557
Primary

Change From Baseline in Neurocognitive Performance at 1 Week Post Treatment (Fluid Cognition)

Participants would complete a computerized batteries (Penn Computerized Neuropsychological Battery and NIH Cognition Battery). Tasks would assess the following domains: information-processing speed, executive function, sustained attention/vigilance, verbal memory, working-memory capacity, inhibition/impulsivity, and sensorimotor function. This composite includes all the tests noted above that are fluid ability measures: Flanker, Dimensional Change Card Sort, Picture Sequence Memory, List Sorting and Pattern Comparison. This composite score is derived by averaging the standard scores of each of the measures, and then deriving standard scores based on this new distribution. The T-score has a mean of 50 in the general population and a SD of 10. Scores higher than the mean indicate better performance.

Time frame: Post-treatment (within 1 week of completing rTMS)

ArmMeasureValue (MEAN)Dispersion
Dose 1Change From Baseline in Neurocognitive Performance at 1 Week Post Treatment (Fluid Cognition)72.500 score on a scaleStandard Deviation 5.916
Dose 2Change From Baseline in Neurocognitive Performance at 1 Week Post Treatment (Fluid Cognition)63.750 score on a scaleStandard Deviation 5.852
Dose 3Change From Baseline in Neurocognitive Performance at 1 Week Post Treatment (Fluid Cognition)67.750 score on a scaleStandard Deviation 13.5
Dose 4Change From Baseline in Neurocognitive Performance at 1 Week Post Treatment (Fluid Cognition)69.500 score on a scaleStandard Deviation 11.79
Dose 5Change From Baseline in Neurocognitive Performance at 1 Week Post Treatment (Fluid Cognition)70.000 score on a scaleStandard Deviation 11.165
Dose 6Change From Baseline in Neurocognitive Performance at 1 Week Post Treatment (Fluid Cognition)73.250 score on a scaleStandard Deviation 5.252
Dose 7Change From Baseline in Neurocognitive Performance at 1 Week Post Treatment (Fluid Cognition)71.000 score on a scaleStandard Deviation 10.1
Dose 8Change From Baseline in Neurocognitive Performance at 1 Week Post Treatment (Fluid Cognition)71.667 score on a scaleStandard Deviation 5.508
Dose 9Change From Baseline in Neurocognitive Performance at 1 Week Post Treatment (Fluid Cognition)69.000 score on a scaleStandard Deviation 9.899
Dose 10Change From Baseline in Neurocognitive Performance at 1 Week Post Treatment (Fluid Cognition)63.750 score on a scaleStandard Deviation 7.588
Primary

Mean Score of Neurocognitive Performance (Fluid Cognition)

Participants would complete a computerized batteries (Penn Computerized Neuropsychological Battery and NIH Cognition Battery). Tasks would assess the following domains: information-processing speed, executive function, sustained attention/vigilance, verbal memory, working-memory capacity, inhibition/impulsivity, and sensorimotor function. This composite includes all the tests noted above that are fluid ability measures: Flanker, Dimensional Change Card Sort, Picture Sequence Memory, List Sorting and Pattern Comparison. This composite score is derived by averaging the standard scores of each of the measures, and then deriving standard scores based on this new distribution. Higher values (positive changes from baseline) indicate better performance. The T-score has a mean of 50 in the general population and a SD of 10. Scores higher than the mean indicate better performance.

Time frame: Baseline (Day 1)

ArmMeasureValue (MEAN)Dispersion
Dose 1Mean Score of Neurocognitive Performance (Fluid Cognition)63.500 score on a scaleStandard Deviation 5.447
Dose 2Mean Score of Neurocognitive Performance (Fluid Cognition)50.250 score on a scaleStandard Deviation 10.079
Dose 3Mean Score of Neurocognitive Performance (Fluid Cognition)59.750 score on a scaleStandard Deviation 13.598
Dose 4Mean Score of Neurocognitive Performance (Fluid Cognition)57.250 score on a scaleStandard Deviation 13.15
Dose 5Mean Score of Neurocognitive Performance (Fluid Cognition)60.500 score on a scaleStandard Deviation 12.819
Dose 6Mean Score of Neurocognitive Performance (Fluid Cognition)65.250 score on a scaleStandard Deviation 5.795
Dose 7Mean Score of Neurocognitive Performance (Fluid Cognition)58.250 score on a scaleStandard Deviation 9.777
Dose 8Mean Score of Neurocognitive Performance (Fluid Cognition)61.000 score on a scaleStandard Deviation 3.464
Dose 9Mean Score of Neurocognitive Performance (Fluid Cognition)70.333 score on a scaleStandard Deviation 9.866
Dose 10Mean Score of Neurocognitive Performance (Fluid Cognition)58.250 score on a scaleStandard Deviation 4.856
Secondary

Mean Score of Neurocognitive Performance (Stress Total Score)

is a 99-item self-report questionnaire assessing emotional and psychological symptoms across 18 subscales. For this outcome, a subset of items was used to assess stress resilience, likely drawn from the Well-Being or related subscales. Each item is rated on a 5-point Likert scale from 1 (Not at all) to 5 (Extremely). Scores were summed across selected items. Minimum possible score: 0 Maximum possible score: 15 Lower scores indicate greater resilience and better emotional functioning. Higher scores indicate greater symptom severity and worse outcomes.

Time frame: Post-treatment (within 1 month of completing rTMS)

ArmMeasureValue (MEAN)Dispersion
Dose 1Mean Score of Neurocognitive Performance (Stress Total Score)13.333 score on a scaleStandard Deviation 3.055
Dose 2Mean Score of Neurocognitive Performance (Stress Total Score)11.000 score on a scaleStandard Deviation 3.606
Dose 3Mean Score of Neurocognitive Performance (Stress Total Score)11.000 score on a scaleStandard Deviation 3.367
Dose 4Mean Score of Neurocognitive Performance (Stress Total Score)6.750 score on a scaleStandard Deviation 4.787
Dose 5Mean Score of Neurocognitive Performance (Stress Total Score)5.250 score on a scaleStandard Deviation 2.217
Dose 6Mean Score of Neurocognitive Performance (Stress Total Score)7.750 score on a scaleStandard Deviation 7.676
Dose 7Mean Score of Neurocognitive Performance (Stress Total Score)8.667 score on a scaleStandard Deviation 6.028
Dose 8Mean Score of Neurocognitive Performance (Stress Total Score)7.000 score on a scaleStandard Deviation 7
Dose 9Mean Score of Neurocognitive Performance (Stress Total Score)13.667 score on a scaleStandard Deviation 10.017
Dose 10Mean Score of Neurocognitive Performance (Stress Total Score)7.500 score on a scaleStandard Deviation 2.646
Secondary

Mean Score of Neurocognitive Performance (Stress Total Score)

is a 99-item self-report questionnaire assessing emotional and psychological symptoms across 18 subscales. For this outcome, a subset of items was used to assess stress resilience, likely drawn from the Well-Being or related subscales. Each item is rated on a 5-point Likert scale from 1 (Not at all) to 5 (Extremely). Scores were summed across selected items. Minimum possible score: 0 Maximum possible score: 15 Lower scores indicate greater resilience and better emotional functioning. Higher scores indicate greater symptom severity and worse outcomes.

Time frame: Baseline (Day 1)

ArmMeasureValue (MEAN)Dispersion
Dose 1Mean Score of Neurocognitive Performance (Stress Total Score)12.500 score on a scaleStandard Deviation 3.109
Dose 2Mean Score of Neurocognitive Performance (Stress Total Score)11.250 score on a scaleStandard Deviation 6.702
Dose 3Mean Score of Neurocognitive Performance (Stress Total Score)13.500 score on a scaleStandard Deviation 3.873
Dose 4Mean Score of Neurocognitive Performance (Stress Total Score)9.750 score on a scaleStandard Deviation 4.856
Dose 5Mean Score of Neurocognitive Performance (Stress Total Score)6.250 score on a scaleStandard Deviation 5.909
Dose 6Mean Score of Neurocognitive Performance (Stress Total Score)9.750 score on a scaleStandard Deviation 6.602
Dose 7Mean Score of Neurocognitive Performance (Stress Total Score)9.750 score on a scaleStandard Deviation 3.304
Dose 8Mean Score of Neurocognitive Performance (Stress Total Score)7.000 score on a scaleStandard Deviation 7.937
Dose 9Mean Score of Neurocognitive Performance (Stress Total Score)13.333 score on a scaleStandard Deviation 5.033
Dose 10Mean Score of Neurocognitive Performance (Stress Total Score)11.250 score on a scaleStandard Deviation 6.397
Secondary

Mean Score of Neurocognitive Performance (Stress Total Score)

is a 99-item self-report questionnaire assessing emotional and psychological symptoms across 18 subscales. For this outcome, a subset of items was used to assess stress resilience, likely drawn from the Well-Being or related subscales. Each item is rated on a 5-point Likert scale from 1 (Not at all) to 5 (Extremely). Scores were summed across selected items. Minimum possible score: 0 Maximum possible score: 15 Lower scores indicate greater resilience and better emotional functioning. Higher scores indicate greater symptom severity and worse outcomes.

Time frame: Post-treatment (within 1 week of completing rTMS)

ArmMeasureValue (MEAN)Dispersion
Dose 1Mean Score of Neurocognitive Performance (Stress Total Score)15.500 score on a scaleStandard Deviation 4.655
Dose 2Mean Score of Neurocognitive Performance (Stress Total Score)13.500 score on a scaleStandard Deviation 3.109
Dose 3Mean Score of Neurocognitive Performance (Stress Total Score)11.500 score on a scaleStandard Deviation 6.351
Dose 4Mean Score of Neurocognitive Performance (Stress Total Score)11.000 score on a scaleStandard Deviation 4.082
Dose 5Mean Score of Neurocognitive Performance (Stress Total Score)6.750 score on a scaleStandard Deviation 4.573
Dose 6Mean Score of Neurocognitive Performance (Stress Total Score)11.000 score on a scaleStandard Deviation 5.354
Dose 7Mean Score of Neurocognitive Performance (Stress Total Score)11.500 score on a scaleStandard Deviation 7.55
Dose 8Mean Score of Neurocognitive Performance (Stress Total Score)8.333 score on a scaleStandard Deviation 8.505
Dose 9Mean Score of Neurocognitive Performance (Stress Total Score)14.000 score on a scaleStandard Deviation 7.211
Dose 10Mean Score of Neurocognitive Performance (Stress Total Score)7.500 score on a scaleStandard Deviation 2.646
Secondary

Mean Score of Neurocognitive Performance (WINSCAT Composite)

The WINSCAT battery includes 5 subtests: Code Substitution (CDS), Code Substitution Delayed Recognition (CDD), Delayed Matching to Sample (MSP), Mathematical Processing (MTH), and Running Memory Continuous Performance (CPT). Each subtest produces a standardized score (range: 0-100). Composite score is the sum of all subtests (range: 0-500). Higher scores indicate better cognitive performance. This measure reflects neurocognitive status 1 month after rTMS treatment. Scores are compared to baseline and 1-week post-treatment to assess sustained or enhanced cognitive improvement. WINSCAT evaluates attention, memory, visual processing, and executive function.

Time frame: Post-treatment (within 1 month of completing rTMS)

ArmMeasureValue (MEAN)Dispersion
Dose 1Mean Score of Neurocognitive Performance (WINSCAT Composite)401.667 score on a scaleStandard Deviation 75.646
Dose 2Mean Score of Neurocognitive Performance (WINSCAT Composite)380.333 score on a scaleStandard Deviation 42.618
Dose 3Mean Score of Neurocognitive Performance (WINSCAT Composite)405.750 score on a scaleStandard Deviation 50.328
Dose 4Mean Score of Neurocognitive Performance (WINSCAT Composite)414.750 score on a scaleStandard Deviation 95.73
Dose 5Mean Score of Neurocognitive Performance (WINSCAT Composite)448.250 score on a scaleStandard Deviation 55.883
Dose 6Mean Score of Neurocognitive Performance (WINSCAT Composite)424.500 score on a scaleStandard Deviation 40.673
Dose 7Mean Score of Neurocognitive Performance (WINSCAT Composite)440.667 score on a scaleStandard Deviation 26.312
Dose 8Mean Score of Neurocognitive Performance (WINSCAT Composite)431.667 score on a scaleStandard Deviation 36.638
Dose 9Mean Score of Neurocognitive Performance (WINSCAT Composite)435.667 score on a scaleStandard Deviation 62.405
Dose 10Mean Score of Neurocognitive Performance (WINSCAT Composite)429.250 score on a scaleStandard Deviation 20.271
Secondary

Mean Score of Neurocognitive Performance (WINSCAT Composite)

The WINSCAT battery includes 5 subtests: Code Substitution (CDS), Code Substitution Delayed Recognition (CDD), Delayed Matching to Sample (MSP), Mathematical Processing (MTH), and Running Memory Continuous Performance (CPT). Each subtest produces a standardized score (range: 0-100). Composite score is the sum of all subtests (range: 0-500). Higher scores indicate better cognitive performance. Baseline scores reflect initial neurocognitive status. WINSCAT assesses attention, memory, visual processing, and executive function.

Time frame: Baseline (Day 1)

ArmMeasureValue (MEAN)Dispersion
Dose 1Mean Score of Neurocognitive Performance (WINSCAT Composite)398.250 score on a scaleStandard Deviation 70.415
Dose 2Mean Score of Neurocognitive Performance (WINSCAT Composite)302.500 score on a scaleStandard Deviation 61.278
Dose 3Mean Score of Neurocognitive Performance (WINSCAT Composite)382.250 score on a scaleStandard Deviation 41.428
Dose 4Mean Score of Neurocognitive Performance (WINSCAT Composite)366.250 score on a scaleStandard Deviation 98.524
Dose 5Mean Score of Neurocognitive Performance (WINSCAT Composite)408.250 score on a scaleStandard Deviation 71.481
Dose 6Mean Score of Neurocognitive Performance (WINSCAT Composite)367.750 score on a scaleStandard Deviation 30.511
Dose 7Mean Score of Neurocognitive Performance (WINSCAT Composite)435.750 score on a scaleStandard Deviation 14.569
Dose 8Mean Score of Neurocognitive Performance (WINSCAT Composite)382.000 score on a scaleStandard Deviation 77.544
Dose 9Mean Score of Neurocognitive Performance (WINSCAT Composite)427.000 score on a scaleStandard Deviation 17.088
Dose 10Mean Score of Neurocognitive Performance (WINSCAT Composite)400.750 score on a scaleStandard Deviation 54.414
Secondary

Mean Score of Neurocognitive Performance (WINSCAT Composite)

The WINSCAT battery includes 5 subtests: Code Substitution (CDS), Code Substitution Delayed Recognition (CDD), Delayed Matching to Sample (MSP), Mathematical Processing (MTH), and Running Memory Continuous Performance (CPT). Each subtest produces a standardized score (range: 0-100). Composite score is the sum of all subtests (range: 0-500). Higher scores indicate better cognitive performance. This measure reflects post-treatment neurocognitive status following rTMS. Scores are compared to baseline to assess improvement. WINSCAT evaluates attention, memory, visual processing, and executive function.

Time frame: Post-treatment (within 1 week of completing rTMS)

ArmMeasureValue (MEAN)Dispersion
Dose 1Mean Score of Neurocognitive Performance (WINSCAT Composite)406.750 score on a scaleStandard Deviation 76.129
Dose 2Mean Score of Neurocognitive Performance (WINSCAT Composite)321.250 score on a scaleStandard Deviation 28.028
Dose 3Mean Score of Neurocognitive Performance (WINSCAT Composite)388.250 score on a scaleStandard Deviation 31.795
Dose 4Mean Score of Neurocognitive Performance (WINSCAT Composite)403.250 score on a scaleStandard Deviation 74.813
Dose 5Mean Score of Neurocognitive Performance (WINSCAT Composite)445.000 score on a scaleStandard Deviation 94.278
Dose 6Mean Score of Neurocognitive Performance (WINSCAT Composite)370.250 score on a scaleStandard Deviation 18.554
Dose 7Mean Score of Neurocognitive Performance (WINSCAT Composite)459.000 score on a scaleStandard Deviation 46.819
Dose 8Mean Score of Neurocognitive Performance (WINSCAT Composite)398.000 score on a scaleStandard Deviation 11.358
Dose 9Mean Score of Neurocognitive Performance (WINSCAT Composite)503.667 score on a scaleStandard Deviation 15.275
Dose 10Mean Score of Neurocognitive Performance (WINSCAT Composite)449.000 score on a scaleStandard Deviation 46.275
Secondary

Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale

The Connor Davidson Resilience Scale (CD-RISC 10) is a unidimensional self-reported scale consisting of 10-items measuring resilience. Respondents rate items on a 5-point Likert scale, ranging from 0 (not true at all) to 4 (true nearly all the time). Each item has a minimum score of 0 and a maximum score of 4. The minimum value is a 0 and the maximum value is a 100. A higher score indicates higher resilience, which indicates a better outcome.

Time frame: Post-treatment (within 1 week of completing rTMS)

ArmMeasureValue (MEAN)Dispersion
Dose 1Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale72.000 score on a scaleStandard Deviation 11.804
Dose 2Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale70.750 score on a scaleStandard Deviation 7.848
Dose 3Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale76.000 score on a scaleStandard Deviation 16.693
Dose 4Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale79.500 score on a scaleStandard Deviation 9.678
Dose 5Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale80.000 score on a scaleStandard Deviation 4.32
Dose 6Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale75.000 score on a scaleStandard Deviation 7.024
Dose 7Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale84.000 score on a scaleStandard Deviation 9.592
Dose 8Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale78.333 score on a scaleStandard Deviation 15.044
Dose 9Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale69.000 score on a scaleStandard Deviation 19.157
Dose 10Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale73.000 score on a scaleStandard Deviation 7.958
Secondary

Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale

The Connor Davidson Resilience Scale (CD-RISC 10) is a unidimensional self-reported scale consisting of 10-items measuring resilience. Respondents rate items on a 5-point Likert scale, ranging from 0 (not true at all) to 4 (true nearly all the time). Each item has a minimum score of 0 and a maximum score of 4. The minimum value is a 0 and the maximum value is a 100. A higher score indicates higher resilience, which indicates a better outcome.

Time frame: Post-treatment (within 1 month of completing rTMS)

ArmMeasureValue (MEAN)Dispersion
Dose 1Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale69.000 score on a scaleStandard Deviation 9.695
Dose 2Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale68.000 score on a scaleStandard Deviation 17.795
Dose 3Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale80.000 score on a scaleStandard Deviation 13.241
Dose 4Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale82.000 score on a scaleStandard Deviation 12.702
Dose 5Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale84.500 score on a scaleStandard Deviation 9.183
Dose 6Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale73.000 score on a scaleStandard Deviation 7.303
Dose 7Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale81.500 score on a scaleStandard Deviation 10.755
Dose 8Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale80.667 score on a scaleStandard Deviation 16.042
Dose 9Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale68.667 score on a scaleStandard Deviation 22.03
Dose 10Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale71.500 score on a scaleStandard Deviation 5.196
Secondary

Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale

Participants would complete a series of questionnaires Connor Davidson Resilience Scale is a self-reported scale consisting of 10-items measuring resilience. Respondents rate items on a 5-point Likert scale, ranging from 0 (not true at all) to 4 (true nearly all the time). Each item has a minimum score of 0 and a maximum score of 4. The minimum value is a 0 and the maximum value is a 100. A higher score indicates higher resilience, which indicates a better outcome. -Questions are rated on a scale from 0-4, where a higher score reflects greater resilience.

Time frame: Baseline (Day 1)

ArmMeasureValue (MEAN)Dispersion
Dose 1Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale70.750 score on a scaleStandard Deviation 10.079
Dose 2Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale74.250 score on a scaleStandard Deviation 12.339
Dose 3Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale75.250 score on a scaleStandard Deviation 12.842
Dose 4Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale80.000 score on a scaleStandard Deviation 10.801
Dose 5Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale83.250 score on a scaleStandard Deviation 7.274
Dose 6Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale72.750 score on a scaleStandard Deviation 9.708
Dose 7Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale77.500 score on a scaleStandard Deviation 5.447
Dose 8Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale85.333 score on a scaleStandard Deviation 11.06
Dose 9Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale69.333 score on a scaleStandard Deviation 19.63
Dose 10Mean Score of Stress Resilience as Assessed by Connor Davidson Resilience Scale74.250 score on a scaleStandard Deviation 2.986
Secondary

Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II

The Inventory of Depression and Anxiety Symptoms-II (IDAS-II) is a 99-item self-report questionnaire assessing emotional and psychological symptoms across 18 subscales. Each item is rated on a 5-point Likert scale from 1 (Not at all) to 5 (Extremely). In this study, a composite score was calculated by summing responses across multiple relevant subscales (e.g., Dysphoria, Panic, Insomnia, Well-Being) to assess overall emotional distress and stress resilience. Minimum possible score: 99 Maximum possible score: 495 Higher scores indicate greater symptom severity and worse outcomes. Lower scores reflect better emotional functioning and greater resilience.

Time frame: Post-treatment (within 1 week of completing rTMS)

ArmMeasureValue (MEAN)Dispersion
Dose 1Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II142.750 score on a scaleStandard Deviation 9.5
Dose 2Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II140.250 score on a scaleStandard Deviation 12.5
Dose 3Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II140.750 score on a scaleStandard Deviation 21.391
Dose 4Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II128.500 score on a scaleStandard Deviation 14.617
Dose 5Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II125.250 score on a scaleStandard Deviation 4.349
Dose 6Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II142.000 score on a scaleStandard Deviation 22.672
Dose 7Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II135.750 score on a scaleStandard Deviation 12.258
Dose 8Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II140.667 score on a scaleStandard Deviation 24.786
Dose 9Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II133.333 score on a scaleStandard Deviation 11.06
Dose 10Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II136.500 score on a scaleStandard Deviation 18.083
Secondary

Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II

The Inventory of Depression and Anxiety Symptoms-II (IDAS-II) is a 99-item self-report questionnaire assessing emotional and psychological symptoms across 18 subscales. Each item is rated on a 5-point Likert scale from 1 (Not at all) to 5 (Extremely). In this study, a composite score was calculated by summing responses across multiple relevant subscales (e.g., Dysphoria, Panic, Insomnia, Well-Being) to assess overall emotional distress and stress resilience. Minimum possible score: 99 (if all items scored 1) Maximum possible score: 495 (if all items scored 5) Higher scores indicate greater symptom severity and worse outcomes. Lower scores reflect better emotional functioning and greater resilience.

Time frame: Baseline (Day 1)

ArmMeasureValue (MEAN)Dispersion
Dose 1Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II136.250 score on a scaleStandard Deviation 9.032
Dose 2Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II142.750 score on a scaleStandard Deviation 18.209
Dose 3Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II144.500 score on a scaleStandard Deviation 12.124
Dose 4Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II129.000 score on a scaleStandard Deviation 10.52
Dose 5Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II127.750 score on a scaleStandard Deviation 4.573
Dose 6Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II167.250 score on a scaleStandard Deviation 47.594
Dose 7Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II133.500 score on a scaleStandard Deviation 14.364
Dose 8Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II140.000 score on a scaleStandard Deviation 22.65
Dose 9Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II136.667 score on a scaleStandard Deviation 17.388
Dose 10Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II147.000 score on a scaleStandard Deviation 25.534
Secondary

Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II

The Inventory of Depression and Anxiety Symptoms-II (IDAS-II) is a 99-item self-report questionnaire assessing emotional and psychological symptoms across 18 subscales. Each item is rated on a 5-point Likert scale from 1 (Not at all) to 5 (Extremely). In this study, a composite score was calculated by summing responses across multiple relevant subscales (e.g., Dysphoria, Panic, Insomnia, Well-Being) to assess overall emotional distress and stress resilience. Minimum possible score: 99 Maximum possible score: 495 Higher scores indicate greater symptom severity and worse outcomes. Lower scores reflect better emotional functioning and greater resilience.

Time frame: Post-treatment (within 1 month of completing rTMS)

ArmMeasureValue (MEAN)Dispersion
Dose 1Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II140.250 score on a scaleStandard Deviation 11.295
Dose 2Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II138.500 score on a scaleStandard Deviation 17.311
Dose 3Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II142.750 score on a scaleStandard Deviation 14.175
Dose 4Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II127.000 score on a scaleStandard Deviation 10.551
Dose 5Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II122.500 score on a scaleStandard Deviation 3.697
Dose 6Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II150.750 score on a scaleStandard Deviation 31.879
Dose 7Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II134.250 score on a scaleStandard Deviation 14.818
Dose 8Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II139.667 score on a scaleStandard Deviation 21.127
Dose 9Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II128.667 score on a scaleStandard Deviation 15.631
Dose 10Mean Score of Stress Resilience as Assessed by Inventory of Depression and Anxiety Symptoms-II136.000 score on a scaleStandard Deviation 15.1
Secondary

Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10

The investigators will use the Perceived Stress Scale 10 (PSS-10) to assess perceived stress using a 5-point Likert scale. Scoring Instructions: Total score is determined by adding together the scores of each of the four items. Questions 2 and 3 are reverse coded. Questions 1 and 4: 0 = Never; 1 = Almost never; 2 = Sometimes; 3 = Fairly often; 4 = Very often Questions 2 and 3: 4 = Never; 3 = Almost never; 2 = Sometimes; 1 = Fairly often; 0 = Very often. Scores range from 0 to 40 with higher scores indicating more stress.

Time frame: Post-treatment (within 1 month of completing rTMS)

ArmMeasureValue (MEAN)Dispersion
Dose 1Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-1013.000 score on a scaleStandard Deviation 2.582
Dose 2Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-1012.750 score on a scaleStandard Deviation 2.986
Dose 3Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-108.250 score on a scaleStandard Deviation 4.031
Dose 4Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-106.750 score on a scaleStandard Deviation 4.787
Dose 5Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-105.250 score on a scaleStandard Deviation 2.217
Dose 6Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-1010.500 score on a scaleStandard Deviation 6.856
Dose 7Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-109.250 score on a scaleStandard Deviation 3.862
Dose 8Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-105.667 score on a scaleStandard Deviation 7.371
Dose 9Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-1013.000 score on a scaleStandard Deviation 11
Dose 10Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-107.500 score on a scaleStandard Deviation 2.646
Secondary

Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10

The investigators will use the Perceived Stress Scale 10 (PSS-10) to assess perceived stress using a 5-point Likert scale. Scoring Instructions: Total score is determined by adding together the scores of each of the four items. Questions 2 and 3 are reverse coded. Questions 1 and 4: 0 = Never; 1 = Almost never; 2 = Sometimes; 3 = Fairly often; 4 = Very often Questions 2 and 3: 4 = Never; 3 = Almost never; 2 = Sometimes; 1 = Fairly often; 0 = Very often. Scores range from 0 to 40 with higher scores indicating more stress.

Time frame: Post-treatment (within 1 week of completing rTMS)

ArmMeasureValue (MEAN)Dispersion
Dose 1Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-1015.500 score on a scaleStandard Deviation 4.655
Dose 2Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-1014.000 score on a scaleStandard Deviation 2.449
Dose 3Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-1010.000 score on a scaleStandard Deviation 6.88
Dose 4Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-1011.000 score on a scaleStandard Deviation 4.082
Dose 5Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-106.750 score on a scaleStandard Deviation 4.573
Dose 6Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-1012.750 score on a scaleStandard Deviation 3.594
Dose 7Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-106.750 score on a scaleStandard Deviation 3.594
Dose 8Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-109.667 score on a scaleStandard Deviation 7.234
Dose 9Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-1013.667 score on a scaleStandard Deviation 7.767
Dose 10Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-107.500 score on a scaleStandard Deviation 2.646
Secondary

Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-10

The investigators will use the Perceived Stress Scale 10 (PSS-10) to assess perceived stress using a 5-point Likert scale. Scoring Instructions: Total score is determined by adding together the scores of each of the four items. Questions 2 and 3 are reverse coded. Questions 1 and 4: 0 = Never; 1 = Almost never; 2 = Sometimes; 3 = Fairly often; 4 = Very often Questions 2 and 3: 4 = Never; 3 = Almost never; 2 = Sometimes; 1 = Fairly often; 0 = Very often. Scores range from 0 to 40 with higher scores indicating more stress.

Time frame: Baseline (Day 1)

ArmMeasureValue (MEAN)Dispersion
Dose 1Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-1012.500 score on a scaleStandard Deviation 3.109
Dose 2Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-1012.500 score on a scaleStandard Deviation 5.508
Dose 3Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-1012.500 score on a scaleStandard Deviation 4.796
Dose 4Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-109.750 score on a scaleStandard Deviation 4.856
Dose 5Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-106.250 score on a scaleStandard Deviation 5.909
Dose 6Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-1011.500 score on a scaleStandard Deviation 5.802
Dose 7Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-107.250 score on a scaleStandard Deviation 5.56
Dose 8Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-108.667 score on a scaleStandard Deviation 6.429
Dose 9Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-1012.333 score on a scaleStandard Deviation 6.658
Dose 10Mean Score of Stress Resilience as Assessed by Perceived Stress Scale-1011.250 score on a scaleStandard Deviation 6.397

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026